Payment overview · 2025
General Payments
$673.46
25 reported records · 12 companies
Healthcare provider profile · identity verified
Daniel A Trejo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BASTROP, LA · NPI 1093766925
Verified facts
What the public records show
CMS Open Payments records show Daniel A Trejo, M.D. received $673.46 in general payments during 2025 across 25 reported records.
Astellas Pharma US Inc accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $172.20 | 25.6% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $134.30 | 19.9% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $118.77 | 17.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.50 | 9.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.88 | 7.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $33.25 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.91 | 3.7% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $20.00 | 3.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.52 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.79 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.78 | 2.2% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.56 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.97 | 24 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $172.20 | 10 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $118.77 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.88 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $40.83 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $33.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 425 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 125 |
| Gabapentin | Gabapentin | 382 | 92 |
| Losartan Potassium | Losartan Potassium | 282 | 79 |
| Omeprazole | Omeprazole | 251 | 70 |
| Metformin Hcl | Metformin Hcl | 225 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 216 | 57 |
| Furosemide | Furosemide | 197 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 46 |
| Potassium Chloride | Potassium Chloride | 166 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 52 |
| Eliquis | Apixaban | 161 | 30 |
| Lisinopril | Lisinopril | 159 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 129 | 38 |
| Meloxicam | Meloxicam | 127 | 44 |
| Carvedilol | Carvedilol | 121 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 36 |
| Trazodone Hcl | Trazodone Hcl | 109 | 33 |
| Jardiance | Empagliflozin | 108 | 27 |
| Donepezil Hcl | Donepezil Hcl | 102 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 31 |
| Ozempic | Semaglutide | 99 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 34 |
| Allopurinol | Allopurinol | 95 | 26 |
| Clonazepam | Clonazepam | 93 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 35 |
| Kerendia | Finerenone | 83 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 83 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 18 |
| Tramadol Hcl | Tramadol Hcl | 70 | 30 |
| Linzess | Linaclotide | 69 | 16 |
| Clonidine Hcl | Clonidine Hcl | 63 | 25 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 25 |
| Buspirone Hcl | Buspirone Hcl | 57 | 18 |
| Simvastatin | Simvastatin | 57 | 17 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 20 |
| Promethazine Hcl | Promethazine Hcl | 53 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 52 | 16 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Prednisone | Prednisone | 49 | 17 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Tradjenta | Linagliptin | 48 | suppressed |
| Valsartan | Valsartan | 47 | 20 |
| Estradiol | Estradiol | 46 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 15 |
| Alprazolam | Alprazolam | 45 | 17 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Glimepiride | Glimepiride | 45 | 15 |
| Ibuprofen | Ibuprofen | 45 | 14 |
| Famotidine | Famotidine | 43 | 16 |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 12 |
| Nifedipine Er | Nifedipine | 42 | 21 |
| Trulicity | Dulaglutide | 42 | 11 |
| Mounjaro | Tirzepatide | 41 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Bumetanide | Bumetanide | 36 | 16 |
| Colchicine | Colchicine | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 13 |
| Finasteride | Finasteride | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Memantine Hcl | Memantine Hcl | 34 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Sotalol | Sotalol Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 21 |
| Celecoxib | Celecoxib | 28 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 28 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 28 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | 11 |
| Baclofen | Baclofen | 27 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | 13 |
| Glipizide | Glipizide | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Nystatin | Nystatin | 25 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Atenolol | Atenolol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $673.46 · 25 records | Astellas Pharma US Inc | AUSTEDO XR, CAPLYTA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KEVEYIS, MINIMED 780G, MOUNJARO, OMNIPOD, PYRUKYND, VRAYLAR, Veozah, ZURZUVAE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error